Literature DB >> 2422280

Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.

D E Kern, J P Klarnet, M C Jensen, P D Greenberg.   

Abstract

The roles of Class II-restricted L3T4+ T cells and of accessory cells (AC) during the in vitro generation of Class I-restricted Lyt-2+ cytotoxic T cells (CTL) specific for a Class II-negative syngeneic tumor cell line, FBL, was examined. Treatment of responder FBL-immune spleen cells with alpha L3T4 plus complement before culture, as well as the direct addition of alpha L3T4 to cultures, diminished the generation of FBL-specific CTL. The contribution of L3T4+ cells could be completely replaced by the addition of exogenous cytokines. The data demonstrate that the optimal generation of FBL-specific Lyt-2+ CTL requires the presence of L3T4+ cells, presumably to provide necessary lymphokines. FBL-specific CTL could not be generated from purified FBL-immune T cells in the absence of AC. Syngeneic Ia+ macrophages (M phi), added at the initiation of culture, restored the response of purified T cells. Pretreatment of M phi with ammonium chloride or chloroquine, or the addition of monoclonal alpha I-Ab antibody at the initiation of culture, inhibited the ability of M phi to reconstitute the CTL response. Finally, the addition of exogenous helper factors could replace M phi and reconstitute the FBL-specific response of AC-depleted immune T cells. These results suggest that during the generation of Lyt-2+ CTL to a syngeneic tumor expressing only Class I MHC antigens, Ia+ AC are required to biochemically process antigen released from the tumor cells and present this modified antigen to Class II-restricted T helper cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422280

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Delivery of a MalE CD4(+)-T-cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase.

Authors:  Jiina Loucká; Géraldine Schlecht; Jana Vodolánová; Claude Leclerc; Peter Sebo
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells.

Authors:  J P Zou; J Shimizu; K Ikegame; H Takiuchi; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

Review 4.  Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.

Authors:  H Fujiwara; T Hamaoka
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

5.  Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.

Authors:  M Radrizzani; M Quaia; B Benedetti; S Andreola; M Vaglini; E Galligioni; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.

Authors:  S Kurosawa; M Harada; G Matsuzaki; Y Shinomiya; H Terao; N Kobayashi; K Nomoto
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

7.  Prevention of lymph node metastases by adoptive transfer of CD4+ T lymphocytes admixed with irradiated tumor cells.

Authors:  K Yoshida; T Tachibana
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

8.  The targeting of T-helper cells and tumourcidal macrophages to a B-cell lymphoma using a PPD-monoclonal antibody heteroconjugate.

Authors:  A M Montgomery; M G Wing; P J Lachmann
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

9.  Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.

Authors:  S L Topalian; L Rivoltini; M Mancini; N R Markus; P F Robbins; Y Kawakami; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

10.  The mode of recognition of tumor antigens by noncytolytic-type antitumor T cells: role of antigen-presenting cells and their surface class I and class II H-2 molecules.

Authors:  K Sakamoto; H Nakajima; J Shimizu; T Katagiri; C Kiyotaki; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.